Analysis Of Income And Expense [Abstract]

OSE Immunotherapeutics - Filing #2813125

Concept	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Other revenue	—	—	0 EUR	—	—	—	—	—	—	—	—	0 EUR
Revenue	—	—	18 302 EUR	—	—	—	—	—	—	—	—	26 306 EUR
Material income and expense [abstract]
Research and development expense	—	—	26 893 EUR	—	—	—	—	—	—	—	—	30 550 EUR
Other operating income (expense)	—	—	84,000 EUR	—	—	—	—	—	—	—	—	0 EUR
Selling, general and administrative expense [abstract]
General and administrative expense	—	—	6 672 EUR	—	—	—	—	—	—	—	—	8 608 EUR
Expenses by nature [abstract]
Classes of employee benefits expense [abstract]
Expense from share-based payment transactions with employees	—	—	3 130 EUR	—	—	—	—	—	—	—	—	3 773 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	—	—	61,000 EUR	—	61,000 EUR	—	—	—	—	—	55,000 EUR	55,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	0 EUR	0 EUR	17 699 EUR	0 EUR	61,000 EUR	17 638 EUR	16 825 EUR	0 EUR	0 EUR	0 EUR	55,000 EUR	16 879 EUR